{"id":44856,"topic":"peptides","source":"Sohu","title":"中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发 - Sohu","url":"https://www.sohu.com/a/1053241776_121613636","url_hash":"e433c708fea01100c1178bf3c0078dadb945052a","author":"","summary":"<a href=\"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5xRFRvRTdFQTFSMVVVSzJXc1NQM2ZOMVNTQm5yYl9JUTNDYjF0Q3pNenVBMmRLSVpGNERLeWtPdDFsODBNZXAwWnZTVDhValdWSVFfMkln?oc=5\" target=\"_blank\">中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Sohu</font>","content":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确保治疗效果的同时又可降低高分子量PEG在体内蓄积的风险，从而有利于降低相关不良反应的发生风险，在疗效与安全性之间实现更优平衡。\nIIIa期研究显示，每周一次的维培那肽单药治疗可快速控制血糖，无低血糖风险，同时改善胰岛β细胞功能和胰岛素抵抗，持续降低HbA1c达52周。此外，维培那肽还能减轻体重、降脂和降压，安全性良好。与同类每周一次的GLP-1受体激动剂相比，维培那肽无需剂量滴定，是潜在的优化治疗选择。\nIIIb期研究针对二甲双胍控制不佳的T2DM患者开展。结果显示：维培那肽周制剂作为二甲双胍治疗的联合治疗方案，用于二甲双胍单药治疗控制不佳的中国T2DM患者，可显著改善血糖控制，且耐受性良好。\n此外，在用药体验方面，派达康采用预填充隐藏式针头注射笔，固定剂量（0.97mg）、无需滴定，注射体积仅0.3ml，配有注射提醒和防滚设计，显著提升患者使用便捷性。\n阿里健康作为\"新特药首发阵地\"，致力于帮助创新药更快地从获批到惠及患者。从线上问诊、处方流转、药师审方到长期慢病随访管理，阿里健康提供覆盖新药到达患者的全链条服务，依托亿级活跃用户的精准触达能力与专业慢病管理团队，让新药信息高效到达目标患者群体，让每一位患者都能获得便捷、规范的用药指导。","image_url":"//q1.itc.cn/q_70/images03/20260722/35827d87624a490da77f119f7c192998.jpeg","lang":"zh","published_at":"2026-07-22T02:02:44+00:00","fetched_at":"2026-07-23T22:15:16+00:00","status":"read","starred":0,"extract_state":"ok","summary_auto":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确…","cluster_id":1673824,"extract_retries":0,"extract_error":null,"contract_version":"news_item.v1","format_contract_version":"news_item_formats.v1","dedup_url":"https://www.sohu.com/a/1053241776_121613636","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 747 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":747,"summary_length":221,"usable_text_length":747,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":747,"summary_length":221}},"news_item":{"id":44856,"canonical_url":"https://www.sohu.com/a/1053241776_121613636","source_url":"https://www.sohu.com/a/1053241776_121613636","title":"中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发 - Sohu","source_name":"Sohu","author":null,"published_at":"2026-07-22T02:02:44+00:00","locale":"zh","topic":"peptides","tags":[],"rss_summary":"<a href=\"https://news.google.com/rss/articles/CBMiVkFVX3lxTE5xRFRvRTdFQTFSMVVVSzJXc1NQM2ZOMVNTQm5yYl9JUTNDYjF0Q3pNenVBMmRLSVpGNERLeWtPdDFsODBNZXAwWnZTVDhValdWSVFfMkln?oc=5\" target=\"_blank\">中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发</a>&nbsp;&nbsp;<font color=\"#6f6f6f\">Sohu</font>","full_text":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确保治疗效果的同时又可降低高分子量PEG在体内蓄积的风险，从而有利于降低相关不良反应的发生风险，在疗效与安全性之间实现更优平衡。\nIIIa期研究显示，每周一次的维培那肽单药治疗可快速控制血糖，无低血糖风险，同时改善胰岛β细胞功能和胰岛素抵抗，持续降低HbA1c达52周。此外，维培那肽还能减轻体重、降脂和降压，安全性良好。与同类每周一次的GLP-1受体激动剂相比，维培那肽无需剂量滴定，是潜在的优化治疗选择。\nIIIb期研究针对二甲双胍控制不佳的T2DM患者开展。结果显示：维培那肽周制剂作为二甲双胍治疗的联合治疗方案，用于二甲双胍单药治疗控制不佳的中国T2DM患者，可显著改善血糖控制，且耐受性良好。\n此外，在用药体验方面，派达康采用预填充隐藏式针头注射笔，固定剂量（0.97mg）、无需滴定，注射体积仅0.3ml，配有注射提醒和防滚设计，显著提升患者使用便捷性。\n阿里健康作为\"新特药首发阵地\"，致力于帮助创新药更快地从获批到惠及患者。从线上问诊、处方流转、药师审方到长期慢病随访管理，阿里健康提供覆盖新药到达患者的全链条服务，依托亿级活跃用户的精准触达能力与专业慢病管理团队，让新药信息高效到达目标患者群体，让每一位患者都能获得便捷、规范的用药指导。","excerpt":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确…","extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 747 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1053241776_121613636","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 747 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":747,"summary_length":221,"usable_text_length":747,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":747,"summary_length":221}}},"display_formats":["compact","card","full","digest_section","json"]},"daily_stack_record":{"title":"中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发 - Sohu","url":"https://www.sohu.com/a/1053241776_121613636","summary":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确…","source":"Sohu","date":"2026-07-22T02:02:44+00:00","content":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确保治疗效果的同时又可降低高分子量PEG在体内蓄积的风险，从而有利于降低相关不良反应的发生风险，在疗效与安全性之间实现更优平衡。\nIIIa期研究显示，每周一次的维培那肽单药治疗可快速控制血糖，无低血糖风险，同时改善胰岛β细胞功能和胰岛素抵抗，持续降低HbA1c达52周。此外，维培那肽还能减轻体重、降脂和降压，安全性良好。与同类每周一次的GLP-1受体激动剂相比，维培那肽无需剂量滴定，是潜在的优化治疗选择。\nIIIb期研究针对二甲双胍控制不佳的T2DM患者开展。结果显示：维培那肽周制剂作为二甲双胍治疗的联合治疗方案，用于二甲双胍单药治疗控制不佳的中国T2DM患者，可显著改善血糖控制，且耐受性良好。\n此外，在用药体验方面，派达康采用预填充隐藏式针头注射笔，固定剂量（0.97mg）、无需滴定，注射体积仅0.3ml，配有注射提醒和防滚设计，显著提升患者使用便捷性。\n阿里健康作为\"新特药首发阵地\"，致力于帮助创新药更快地从获批到惠及患者。从线上问诊、处方流转、药师审方到长期慢病随访管理，阿里健康提供覆盖新药到达患者的全链条服务，依托亿级活跃用户的精准触达能力与专业慢病管理团队，让新药信息高效到达目标患者群体，让每一位患者都能获得便捷、规范的用药指导。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1053241776_121613636","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 747 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 747 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":747,"summary_length":221,"usable_text_length":747,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":747,"summary_length":221}},"tags":[]},"fallback_formats":["markdown","json","html"],"actions":{"read":"/item/44856","export_markdown":"/api/items/44856/export?format=markdown","export_json":"/api/items/44856/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.sohu.com/a/1053241776_121613636"},"formats":{"full":{"id":44856,"title":"中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发 - Sohu","url":"https://www.sohu.com/a/1053241776_121613636","source":"Sohu","author":null,"published_at":"2026-07-22T02:02:44+00:00","locale":"zh","topic":"peptides","tags":[],"excerpt":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确…","full_text":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确保治疗效果的同时又可降低高分子量PEG在体内蓄积的风险，从而有利于降低相关不良反应的发生风险，在疗效与安全性之间实现更优平衡。\nIIIa期研究显示，每周一次的维培那肽单药治疗可快速控制血糖，无低血糖风险，同时改善胰岛β细胞功能和胰岛素抵抗，持续降低HbA1c达52周。此外，维培那肽还能减轻体重、降脂和降压，安全性良好。与同类每周一次的GLP-1受体激动剂相比，维培那肽无需剂量滴定，是潜在的优化治疗选择。\nIIIb期研究针对二甲双胍控制不佳的T2DM患者开展。结果显示：维培那肽周制剂作为二甲双胍治疗的联合治疗方案，用于二甲双胍单药治疗控制不佳的中国T2DM患者，可显著改善血糖控制，且耐受性良好。\n此外，在用药体验方面，派达康采用预填充隐藏式针头注射笔，固定剂量（0.97mg）、无需滴定，注射体积仅0.3ml，配有注射提醒和防滚设计，显著提升患者使用便捷性。\n阿里健康作为\"新特药首发阵地\"，致力于帮助创新药更快地从获批到惠及患者。从线上问诊、处方流转、药师审方到长期慢病随访管理，阿里健康提供覆盖新药到达患者的全链条服务，依托亿级活跃用户的精准触达能力与专业慢病管理团队，让新药信息高效到达目标患者群体，让每一位患者都能获得便捷、规范的用药指导。","reading_time_min":1,"extraction":{"state":"ok","confidence":0.9,"error":null,"explanation":"High confidence: full text extraction produced 747 characters.","diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1053241776_121613636","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 747 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":747,"summary_length":221,"usable_text_length":747,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":747,"summary_length":221}}},"quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 747 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":747,"summary_length":221,"usable_text_length":747,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":747,"summary_length":221}},"actions":{"read":"/item/44856","export_markdown":"/api/items/44856/export?format=markdown","export_json":"/api/items/44856/export?format=json","diagnose":"/api/diagnose?url=https%3A//www.sohu.com/a/1053241776_121613636"}},"digest":{"id":44856,"title":"中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发 - Sohu","url":"https://www.sohu.com/a/1053241776_121613636","source":"Sohu","topic":"peptides","published_at":"2026-07-22T02:02:44+00:00","excerpt":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。 派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。 维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确…","quality_bucket":"high","quality_reason":"High confidence: full text extraction produced 747 characters.","reading_time_min":1,"cluster_id":1673824},"card":{"display_title":"中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发 - Sohu","subtitle":"Sohu · 2026-07-22","summary":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。 派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。…","badges":["quality:high"],"links":{"read":"/item/44856","original":"https://www.sohu.com/a/1053241776_121613636","diagnose":"/api/diagnose?url=https%3A//www.sohu.com/a/1053241776_121613636"},"quality_warning":null},"export":{"title":"中国原研1类创新药GLP-1RA周制剂派达康维培那肽注射液在阿里健康首发 - Sohu","url":"https://www.sohu.com/a/1053241776_121613636","summary":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确…","source":"Sohu","date":"2026-07-22T02:02:44+00:00","content":"7月22日，我国自主研发的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂维培那肽注射液（商品名：派达康）在阿里健康首发。\n派达康的创新之处，在于采用了聚乙二醇化（PEG）技术进行修饰，该技术获国家“十三五”重大新药创制专项支持及9项全球发明专利，其上市标志着中国原研糖尿病创新药的关键突破，为广大T2DM患者带来便捷化治疗新选择。\n维培那肽的研究表明，PEG修饰一方面让药物半衰期大幅延长，实现了“每周注射一次”的给药频率；另一方面在确保治疗效果的同时又可降低高分子量PEG在体内蓄积的风险，从而有利于降低相关不良反应的发生风险，在疗效与安全性之间实现更优平衡。\nIIIa期研究显示，每周一次的维培那肽单药治疗可快速控制血糖，无低血糖风险，同时改善胰岛β细胞功能和胰岛素抵抗，持续降低HbA1c达52周。此外，维培那肽还能减轻体重、降脂和降压，安全性良好。与同类每周一次的GLP-1受体激动剂相比，维培那肽无需剂量滴定，是潜在的优化治疗选择。\nIIIb期研究针对二甲双胍控制不佳的T2DM患者开展。结果显示：维培那肽周制剂作为二甲双胍治疗的联合治疗方案，用于二甲双胍单药治疗控制不佳的中国T2DM患者，可显著改善血糖控制，且耐受性良好。\n此外，在用药体验方面，派达康采用预填充隐藏式针头注射笔，固定剂量（0.97mg）、无需滴定，注射体积仅0.3ml，配有注射提醒和防滚设计，显著提升患者使用便捷性。\n阿里健康作为\"新特药首发阵地\"，致力于帮助创新药更快地从获批到惠及患者。从线上问诊、处方流转、药师审方到长期慢病随访管理，阿里健康提供覆盖新药到达患者的全链条服务，依托亿级活跃用户的精准触达能力与专业慢病管理团队，让新药信息高效到达目标患者群体，让每一位患者都能获得便捷、规范的用药指导。","confidence":0.9,"diagnostics_url":"/api/diagnose?url=https%3A//www.sohu.com/a/1053241776_121613636","quality_bucket":"high","failure_kind":"none","retryable":false,"quality_reason":"High confidence: full text extraction produced 747 characters.","quality_profile":{"profile_version":"extraction_quality.v2","bucket":"high","confidence":0.9,"failure_kind":"none","retryable":false,"retry_after_attempts":0,"reason":"High confidence: full text extraction produced 747 characters.","operator_guidance":{"severity":"ok","recommended_action":"trust_full_text","next_step":"Use the extracted full text as the primary article source.","operator_label":"Ready","can_retry":false,"can_use_summary":false,"diagnostics_required":false},"content_depth":{"contract_version":"content_depth.v1","category":"full_text","label":"Full text","has_full_text":true,"has_summary":true,"content_length":747,"summary_length":221,"usable_text_length":747,"source_field":"content"},"legacy_collapsed":false,"signals":{"extract_state":"ok","extract_error":null,"extract_retries":0,"content_length":747,"summary_length":221}},"tags":[],"format_contract_version":"news_item_formats.v1"}}}